Source: Annual Congress 2008 - Mastering pulmonary arterial hypertension: defined by evidence - enhanced by experience
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Humbert (Clamart, France). EARLY: Clear cut evidence in WHO functional class II. Annual Congress 2008 - Mastering pulmonary arterial hypertension: defined by evidence - enhanced by experience

Member's Comments

No comment yet.

Related content which might interest you: PRACTICAL WORKSHOPS II. Source: ERS Course 2016 - Comprehensive management of ventilator-dependent patients Year: 2016 The GOLD stage II frequent exacerbator: characteristics and implications Source: Annual Congress 2009 - COPD: exacerbation and clinical problems Year: 2009 Heterogeneity of stage III and its implication on treatment Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Is GOLD stage 0 a good predictor of the development of COPD? Preliminary results from the ECRHS II Source: Eur Respir J 2005; 26: Suppl. 49, 434s Year: 2005 Influence of HLA class II  DRB1*/DQB1* alleles in phenotypes of Indian patients of sarcoidois. Source: Virtual Congress 2021 – Moving forward in various aspects of sarcoidosis Year: 2021 TIME for a change in practice: insights from the TIME 1, 2, and 3 trials Source: International Congress 2017 – Malignant pleural effusion management in 2017: a review of recent RCTs Year: 2017 What have we learned from big platform trials of COVID? RECOVERY, REMAP-CAP and others Source: Virtual Congress 2021 – How science conquered COVID-19: from big platform trials to patients Year: 2021 SURGERY OF IA STAGE LUNG CARCINOMA. SUBLOBAR RESECTIONS. TO WHOM AND WHEN? Source: International Congress 2019 – Treatment of lung cancer Year: 2019 COPD assessment: I, II, III, IV and/or A, B, C, D Source: Eur Respir J 2014; 43: 949-950 Year: 2014 Major histocompatibility complex class II and BTNL2 associations in sarcoidosis Source: Eur Respir J 2013; 42: 550-553 Year: 2013 TORVAN VERSUS GAP: WHICH PERFORMS BETTER? Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis Year: 2020 Multicenter study on the variability of a novel sleep stage scoring algorithm compared to human experts – part I: learning phase Source: Eur Respir J 2004; 24: Suppl. 48, 117s Year: 2004 REPAIR II: retinoid treatment of emphysema patients on the alpha-1-antitrypsin international registry Source: Eur Respir J 2007; 30: Suppl. 51, 209s Year: 2007 ANGIOTENSIN II BLOCKERS IN OBSTRUCTIVE PULMONARY DISEASE: A RANDOMISED CONTROLLED TRIAL. Source: Eur Respir J 2006; 28: 1292 Year: 2006 Screening for COPD: the gap between logic and evidence Source: Eur Respir Rev 2017; 26: 160113 Year: 2017 Regulation of γ-GCS gene expression by TGF-β in type II epithelial cells: role for Fra-1/AP-1/ARE Source: Eur Respir J 2002; 20: Suppl. 38, 96s Year: 2002 Late Breaking Abstract - Evidence of target engagement and pathway modulation: biomarker analysis of the phase 1b inhaled seralutinib study Source: Virtual Congress 2021 – Pathogenesis and pathophysiology of pulmonary hypertension Year: 2021 Classifying patients as GOLD A–D using the 2017 strategy criteria: impact on efficacy by GOLD stage in the OTEMTO tiotropium+olodaterol clinical trials Source: International Congress 2017 – What is new in COPD diagnosis and classification? Year: 2017 Exacerbation utilities and durations by type: estimates from Phase III benralizumab studies Source: International Congress 2017 – Biomarker-based asthma control Year: 2017